作者:Theresa Gaines、Davita Camp、Renren Bai、Zhongxing Liang、Younghyoun Yoon、Hyunsuk Shim、Suazette Reid Mooring
DOI:10.1016/j.bmc.2016.08.018
日期:2016.11
Targeting the interaction between G-Protein Coupled Receptor, CXCR4, and its natural ligand CXCL12 is a leading strategy to mitigate cancer metastasis and reduce inflammation. Several pyridine-based compounds modeled after known small molecule CXCR4 antagonists, AMD3100 and WZ811, were synthesized. Nine hit compounds were identified. These compounds showed lower binding concentrations than AMD3100
靶向G蛋白偶联受体CXCR4及其天然配体CXCL12之间的相互作用是减轻癌症转移和减少炎症的领先策略。合成了以已知的小分子CXCR4拮抗剂AMD3100和WZ811为模型的几种基于吡啶的化合物。鉴定出九种命中化合物。这些化合物的结合浓度低于AMD3100(1000 nM),九种化合物中的六种有效浓度(EC)小于或等于WZ811(10 nM)。其中两种命中化合物(2g和2w)以比AMD3100(62%)更高的速率抑制转移细胞的侵袭。化合物2g和2w在足爪水肿测试中,也可将炎症抑制在与WZ811相同的范围内,使炎症减少40%。这些初步结果是新型的基于吡啶的CXCR4拮抗剂的有前途的基础。